Literature DB >> 31207711

[Intermediate-high dose cytarabine consolidation therapy in younger adults with acute myeloid leukemia and favorable-intermediate cytogenetic risk: a retrospective study of 124 patients in a single Chinese hospital].

Y Zhang1, J J Qian, L Wang, W J Yu, L P Mao, H Y Tong, H T Meng, W B Qian, J Jin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31207711     DOI： 10.3760/cma.j.issn.0253-2727.2019.05.016

Source DB:  PubMed          Journal:  Zhonghua Xue Ye Xue Za Zhi        ISSN： 0253-2727


× No keyword cloud information.
  2 in total

1.  Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study.

Authors:  Li Ye; Lingsu Gao; Qiansong Cheng; Feng Guo; Liang He; Tingting Yuan; Ming Zhu; Yuanfang Ma; Min Pan; Xiandeng Chu; Meiqi Ding; Guohui Yu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

2.  The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study.

Authors:  Guofeng Chen; Jiaqi Yang; Fuliang Cao; Wei Zhou; Dan Gong; Liren Liu; Dejun Zhou
Journal:  Ann Transl Med       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.